Nyxoah S.A. (NASDAQ:NYXH) Short Interest Down 17.4% in October

Nyxoah S.A. (NASDAQ:NYXH) saw a significant decrease in short interest in the month of October. As of October 31st, there was short interest totalling 58,800 shares, a decrease of 17.4% from the October 15th total of 71,200 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily volume of 63,200 shares, the short-interest ratio is presently 0.9 days.

Institutional Investors Weigh In On Nyxoah

A number of hedge funds have recently made changes to their positions in the business. Iron Triangle Partners LP acquired a new position in shares of Nyxoah during the first quarter valued at $3,413,000. CVI Holdings LLC bought a new position in Nyxoah in the 2nd quarter valued at about $1,292,000. Ikarian Capital LLC acquired a new position in Nyxoah during the 1st quarter valued at about $684,000. Finally, Kovack Advisors Inc. bought a new stake in shares of Nyxoah during the 3rd quarter worth about $96,000.

Wall Street Analysts Forecast Growth

NYXH has been the topic of a number of recent research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $16.00 price target on shares of Nyxoah in a research report on Tuesday, November 5th. Oppenheimer cut their target price on shares of Nyxoah from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Finally, HC Wainwright lowered their target price on Nyxoah from $18.00 to $17.00 and set a “buy” rating for the company in a report on Friday, October 11th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Nyxoah presently has a consensus rating of “Buy” and an average target price of $17.00.

Nyxoah Stock Performance

Shares of NYXH stock traded down $0.21 during trading hours on Friday, reaching $8.22. The stock had a trading volume of 18,951 shares, compared to its average volume of 49,495. The firm has a market capitalization of $205.01 million, a PE ratio of -4.40 and a beta of 1.45. The firm has a 50-day simple moving average of $9.06 and a 200-day simple moving average of $8.73. Nyxoah has a twelve month low of $4.00 and a twelve month high of $20.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.